Published in Infect Genet Evol on December 13, 2010
Understanding the population genetics of Plasmodium vivax is essential for malaria control and elimination. Malar J (2012) 1.32
Differing patterns of selection and geospatial genetic diversity within two leading Plasmodium vivax candidate vaccine antigens. PLoS Negl Trop Dis (2014) 0.96
High genetic diversity of Plasmodium vivax on the north coast of Papua New Guinea. Am J Trop Med Hyg (2013) 0.87
Comparative analysis of field-isolate and monkey-adapted Plasmodium vivax genomes. PLoS Negl Trop Dis (2015) 0.80
Serological responses to a soluble recombinant chimeric Plasmodium vivax circumsporozoite protein in VK210 and VK247 population. Malar J (2013) 0.80
Serological markers to measure recent changes in malaria at population level in Cambodia. Malar J (2016) 0.78
The utility of genomic data for Plasmodium vivax population surveillance. Pathog Glob Health (2015) 0.77
Genetic diversity of Plasmodium Vivax in South of Iran: A cross-sectional study. J Med Life (2015) 0.75
The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg (2001) 11.74
The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis (2010) 6.23
Evolutionary and historical aspects of the burden of malaria. Clin Microbiol Rev (2002) 6.07
Mapping the global extent of malaria in 2005. Trends Parasitol (2006) 4.43
Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax. Science (1989) 2.59
Diagnosing infection levels of four human malaria parasite species by a polymerase chain reaction/ligase detection reaction fluorescent microsphere-based assay. Am J Trop Med Hyg (2006) 2.42
Circumsporozoite protein of Plasmodium vivax: gene cloning and characterization of the immunodominant epitope. Science (1985) 2.41
The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. I. Malariometric indices and immunity. Ann Trop Med Parasitol (1995) 2.24
Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine (2005) 2.21
Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar J (2005) 2.15
Random distribution of mixed species malaria infections in Papua New Guinea. Am J Trop Med Hyg (2000) 2.04
Genetic diversity and multiple infections of Plasmodium vivax malaria in Western Thailand. Am J Trop Med Hyg (2003) 1.98
Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg (2006) 1.93
Detection of Plasmodium vivax by polymerase chain reaction in a field study. J Infect Dis (1993) 1.92
Malaria infections are randomly distributed in diverse holoendemic areas of Papua New Guinea. Am J Trop Med Hyg (2002) 1.73
Age-acquired immunity to a Plasmodium vivax invasion ligand, the duffy binding protein. J Infect Dis (2002) 1.53
Diversity and natural selection in Plasmodium vivax Duffy binding protein gene. Mol Biochem Parasitol (2003) 1.52
Genetic diversity of Plasmodium vivax in Kolkata, India. Malar J (2006) 1.49
An update on the search for a Plasmodium vivax vaccine. Trends Parasitol (2007) 1.41
Plasmodium vivax malaria vaccine development. Mol Immunol (2001) 1.36
Circumsporozoite genotyping of global isolates of Plasmodium vivax from dried blood specimens. J Clin Microbiol (1992) 1.33
Circumsporozoite protein gene diversity among temperate and tropical Plasmodium vivax isolates from Iran. Trop Med Int Health (2006) 1.27
A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect Immun (2006) 1.25
High frequency of genetic diversity of Plasmodium vivax field isolates in Myanmar. Acta Trop (2008) 1.24
Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am J Trop Med Hyg (2005) 1.22
Genetic diversity of Plasmodium vivax isolates from Azerbaijan. Malar J (2004) 1.20
Molecular characterization of Plasmodium vivax clinical isolates in Pakistan and Iran using pvmsp-1, pvmsp-3alpha and pvcsp genes as molecular markers. Parasitol Int (2009) 1.16
Targeted deletion of Plasmodium knowlesi Duffy binding protein confirms its role in junction formation during invasion. Mol Microbiol (2005) 1.16
Observations on early and late post-sporozoite tissue stages in primate malaria. IV. Pre-erythrocytic schizonts and/or hypnozoites of Chesson and North Korean strains of Plasmodium vivax in the chimpanzee. Am J Trop Med Hyg (1986) 1.11
Genetic diversity of Plasmodium vivax Pvcsp and Pvmsp1 in Guyana, South America. Am J Trop Med Hyg (2006) 1.10
Antibodies raised against receptor-binding domain of Plasmodium knowlesi Duffy binding protein inhibit erythrocyte invasion. Mol Biochem Parasitol (2002) 1.09
Genetic structure of Plasmodium vivax isolates from two malaria endemic areas in Afghanistan. Acta Trop (2009) 1.06
Response of Plasmodium vivax variants to chloroquine as determined by microscopy and quantitative polymerase chain reaction. Am J Trop Med Hyg (1993) 1.05
Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein. Int J Parasitol (2004) 1.02
Distribution of Plasmodium vivax variants (VK210, VK247 and P. vivax-like) in three endemic areas of the Amazon region of Brazil and their correlation with chloroquine treatment. Trans R Soc Trop Med Hyg (2000) 1.00
The population dynamics in mosquitoes and humans of two Plasmodium vivax polymorphs distinguished by different circumsporozoite protein repeat regions. Am J Trop Med Hyg (1992) 0.95
Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing P. vivax CS epitopes in Aotus monkeys. Parasite Immunol (1997) 0.94
Susceptibility of Anopheles aquasalis and an. darlingi to Plasmodium vivax VK210 and VK247. Mem Inst Oswaldo Cruz (2006) 0.94
Plasmodium vivax circumsporozoite variants and Duffy blood group genotypes in the Brazilian Amazon region. Trans R Soc Trop Med Hyg (2008) 0.90
Fine epitope specificity of antibodies to region II of the Plasmodium vivax circumsporozoite protein correlates with ability to bind recombinant protein and sporozoites. Acta Trop (1997) 0.85
Evolutionary dynamics of the immunodominant repeats of the Plasmodium vivax malaria-vaccine candidate circumsporozoite protein (CSP). Infect Genet Evol (2010) 0.83
Plasmodium vivax thrombospondin related adhesion protein: immunogenicity and protective efficacy in rodents and Aotus monkeys. Mem Inst Oswaldo Cruz (2007) 0.82
Plasmodium falciparum erythrocyte invasion through glycophorin C and selection for Gerbich negativity in human populations. Nat Med (2002) 3.29
Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci U S A (2010) 2.79
Lymphatic filariasis and onchocerciasis. Lancet (2010) 2.75
The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg (2007) 2.72
Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol (2003) 2.52
Diagnosing infection levels of four human malaria parasite species by a polymerase chain reaction/ligase detection reaction fluorescent microsphere-based assay. Am J Trop Med Hyg (2006) 2.42
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J (2007) 2.30
Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun (2009) 2.22
A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria. Proc Natl Acad Sci U S A (2003) 2.19
The global distribution of the Duffy blood group. Nat Commun (2011) 2.06
Plasmodium malariae and Plasmodium ovale--the "bashful" malaria parasites. Trends Parasitol (2007) 2.04
The epidemiology of malaria in Papua New Guinea. Trends Parasitol (2003) 2.03
R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci U S A (2003) 2.00
Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med (2007) 1.95
Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg (2006) 1.93
A real-time PCR-based assay for detection of Wuchereria bancrofti DNA in blood and mosquitoes. Am J Trop Med Hyg (2006) 1.92
Extensive microsatellite diversity in the human malaria parasite Plasmodium vivax. Gene (2008) 1.89
Can prenatal malaria exposure produce an immune tolerant phenotype? A prospective birth cohort study in Kenya. PLoS Med (2009) 1.87
Integration of control of neglected tropical diseases into health-care systems: challenges and opportunities. Lancet (2010) 1.85
Development of a multiplex PCR-ligase detection reaction assay for diagnosis of infection by the four parasite species causing malaria in humans. J Clin Microbiol (2004) 1.80
The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea. PLoS Negl Trop Dis (2008) 1.74
Malaria infections are randomly distributed in diverse holoendemic areas of Papua New Guinea. Am J Trop Med Hyg (2002) 1.73
Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol (2013) 1.68
A sub-microscopic gametocyte reservoir can sustain malaria transmission. PLoS One (2011) 1.67
The effects of maternal helminth and malaria infections on mother-to-child HIV transmission. AIDS (2005) 1.65
Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc Natl Acad Sci U S A (2008) 1.63
Comparison of diagnostic methods for the detection and quantification of the four sympatric Plasmodium species in field samples from Papua New Guinea. Malar J (2010) 1.60
Insight into the early spread of chloroquine-resistant Plasmodium falciparum infections in Papua New Guinea. J Infect Dis (2005) 1.60
Age-acquired immunity to a Plasmodium vivax invasion ligand, the duffy binding protein. J Infect Dis (2002) 1.53
Diversity and natural selection in Plasmodium vivax Duffy binding protein gene. Mol Biochem Parasitol (2003) 1.52
Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother (2008) 1.50
CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. Clin Immunol (2003) 1.48
Insecticidal bed nets and filariasis transmission in Papua New Guinea. N Engl J Med (2013) 1.48
Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea. PLoS Negl Trop Dis (2011) 1.47
Reduced Plasmodium vivax erythrocyte infection in PNG Duffy-negative heterozygotes. PLoS One (2007) 1.45
Microscopy underestimates the frequency of Plasmodium falciparum infection in symptomatic individuals in a low transmission highland area. Am J Trop Med Hyg (2008) 1.44
Monitoring Plasmodium falciparum growth and development by UV flow cytometry using an optimized Hoechst-thiazole orange staining strategy. Cytometry A (2008) 1.44
Do antenatal parasite infections devalue childhood vaccination? PLoS Negl Trop Dis (2009) 1.43
Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos (2009) 1.41
Antigenic drift in the ligand domain of Plasmodium vivax duffy binding protein confers resistance to inhibitory antibodies. J Infect Dis (2004) 1.40
Geographic and ecologic heterogeneity in elimination thresholds for the major vector-borne helminthic disease, lymphatic filariasis. BMC Biol (2010) 1.38
Real-time quantitative PCR for determining the burden of Plasmodium falciparum parasites during pregnancy and infancy. J Clin Microbiol (2005) 1.36
Onchocerciasis Control: Vision for the Future from a Ghanian perspective. Parasit Vectors (2009) 1.33
Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc Natl Acad Sci U S A (2012) 1.33
Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to Plasmodium vivax malaria. Proc Natl Acad Sci U S A (2011) 1.31
Hemoglobin degradation in malaria-infected erythrocytes determined from live cell magnetophoresis. FASEB J (2006) 1.31
Prenatal T cell immunity to Wuchereria bancrofti and its effect on filarial immunity and infection susceptibility during childhood. J Infect Dis (2006) 1.31
Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol (2006) 1.30
Y chromosome STR haplotypes and the genetic structure of U.S. populations of African, European, and Hispanic ancestry. Genome Res (2003) 1.30
Outbreak of chikungunya virus infection, Vanimo, Papua New Guinea. Emerg Infect Dis (2013) 1.29
Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive protein, and liver-stage antigen 1 vary by ages of subjects and by season in a highland area of Kenya. Infect Immun (2003) 1.29
Enhanced detection of gametocytes by magnetic deposition microscopy predicts higher potential for Plasmodium falciparum transmission. Malar J (2008) 1.28
Distinct Th1- and Th2-Type prenatal cytokine responses to Plasmodium falciparum erythrocyte invasion ligands. Infect Immun (2005) 1.26
CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. Br J Clin Pharmacol (2007) 1.25
Novel Plasmodium vivax dhfr alleles from the Indonesian Archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression system. Antimicrob Agents Chemother (2005) 1.24
How much remains undetected? Probability of molecular detection of human Plasmodia in the field. PLoS One (2011) 1.23
Serologic evidence of arboviral infections among humans in Kenya. Am J Trop Med Hyg (2011) 1.23
Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies. Infect Immun (2009) 1.22
Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humans. J Immunol (2002) 1.22
Umbilical cord-blood infections with Plasmodium falciparum malaria are acquired antenatally in Kenya. J Infect Dis (2006) 1.22
Epitope-specific humoral immunity to Plasmodium vivax Duffy binding protein. Infect Immun (2003) 1.21
Intermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trial. PLoS Med (2012) 1.20
Placental malaria-associated inflammation disturbs the insulin-like growth factor axis of fetal growth regulation. J Infect Dis (2011) 1.18
Active pharmaceutical ingredients for antiretroviral treatment in low- and middle-income countries: a survey. Antivir Ther (2014) 1.15
Whole genome sequencing of field isolates provides robust characterization of genetic diversity in Plasmodium vivax. PLoS Negl Trop Dis (2012) 1.13
Whole genome sequencing of field isolates reveals a common duplication of the Duffy binding protein gene in Malagasy Plasmodium vivax strains. PLoS Negl Trop Dis (2013) 1.13
Influence of maternal filariasis on childhood infection and immunity to Wuchereria bancrofti in Kenya. Infect Immun (2003) 1.12
Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children. Infect Immun (2009) 1.11
Identification of a polymorphic Plasmodium vivax microsatellite marker. Am J Trop Med Hyg (2003) 1.11
Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria. Antimicrob Agents Chemother (2004) 1.10
Placental infection with Plasmodium vivax: a histopathological and molecular study. J Infect Dis (2012) 1.09
PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. J Virol (2004) 1.08
Arbovirus prevalence in mosquitoes, Kenya. Emerg Infect Dis (2011) 1.07
Prenatal malaria immune experience affects acquisition of Plasmodium falciparum merozoite surface protein-1 invasion inhibitory antibodies during infancy. J Immunol (2006) 1.07
De novo assembly of a field isolate genome reveals novel Plasmodium vivax erythrocyte invasion genes. PLoS Negl Trop Dis (2013) 1.07
Increased ratio of tumor necrosis factor-alpha to interleukin-10 production is associated with Schistosoma haematobium-induced urinary-tract morbidity. J Infect Dis (2004) 1.05
A polymerase chain reaction/ligase detection reaction fluorescent microsphere assay to determine Plasmodium falciparum MSP-119 haplotypes. Am J Trop Med Hyg (2007) 1.05
Nigeria Anopheles vector database: an overview of 100 years' research. PLoS One (2011) 1.05
A multiplex ligase detection reaction-fluorescent microsphere assay for simultaneous detection of single nucleotide polymorphisms associated with Plasmodium falciparum drug resistance. J Clin Microbiol (2006) 1.04
Human cord blood CD4+CD25hi regulatory T cells suppress prenatally acquired T cell responses to Plasmodium falciparum antigens. J Immunol (2011) 1.04
Natural acquisition of immunity to Plasmodium vivax: epidemiological observations and potential targets. Adv Parasitol (2013) 1.03